Phase 1b clinical trial of pucotenlimab (hx008), a novel anti-pd-1 monoclonal antibody, combined with gemcitabine and cisplatin in the first-line treatment of metastatic triple-negative breast cancer

HIGHLIGHTS

• who: Jun Cao and collaborators from the Scientific Institute of Romagna for the (IRCCS), Italy Department of Medical Oncology, Fudan University Shanghai Center, Shanghai, China have published the research: Phase 1b clinical trial of pucotenlimab (HX008), a novel anti-PD-1 monoclonal antibody, combined with gemcitabine and cisplatin in the first-line treatment of metastatic triple-negative breast cancer, in the Journal: (JOURNAL)
• what: The phase 1b study was conducted to assess the safety and preliminary antitumor activity of pucotenlimab, along with GP, in Chinese patients with mTNBC in a first-line setting. The main . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.